Antifungal susceptibilities of 113 clinical isolates of Cryptococcus neoformans and candida SP to the new antifungal albaconazole (UR9825) respect to voriconazole and fluconazole

被引:0
|
作者
Morera, Y [1 ]
Torres-Rodríguez, J [1 ]
Jiménez, T [1 ]
机构
[1] Autonomous Univ Barcelona, Fac Med, IMIM,IMAS, Clin & Expt Mycol Grp, E-08193 Barcelona, Spain
来源
关键词
D O I
暂无
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The goal of this study was to assess the Minimal Inhibitory Concentrations (MICs) to the new azoles Albaconazole (ALBA)(1) and Voriconazole (VNZ) in 113 human clinical isolates of Cryptococcus neoformans (N=33) and Candida sp (N=80). Among these 49% were included because of resistance to fluconazole. Testing was done with a broth microdilution method, according to the NCCLS recommendations (M27-A). Eight of the 38 fluconazole resistant isolates presented values 3 4 for VNZ and 5 for ALBA. For both azoles the species with lower geometric mean were Candida dubliniensis and C tropicalis and the high values were for C glabrata. None of the C krusei fluconazole resistant isolates (N=23) showed MICs >0.25 mug/ml for ALBA and 2 of these isolates presented MICs of I mug/ml for VNZ. All the C. neoformans isolates showed MICs less than or equal to 0.5 mug/ml for the two azoles, including two fluconazole resistant strains. Albaconazole and Voriconazole are two new antifungals very active against pathogenic yeasts, including most of fluconazole resistant ones.
引用
收藏
页码:143 / 147
页数:5
相关论文
共 20 条
  • [1] Cryptococcus gattii:: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole
    Morera-López, Y
    Torres-Rodríguez, JM
    Jiménez-Cabello, T
    Baró-Tomás, T
    MEDICAL MYCOLOGY, 2005, 43 (06) : 505 - 510
  • [2] In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds
    Garau, M
    Pereiro, M
    del Palacio, A
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2342 - 2344
  • [3] In vitro susceptibilities of clinical and environmental isolates of Cryptococcus neoformans to five antifungal drugs
    Franzot, SP
    Hamdan, JS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) : 822 - 824
  • [4] Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients
    Burn, AK
    Fothergill, AW
    Kirkpatrick, WR
    Coco, BJ
    Patterson, TF
    McCarthy, DI
    Rinaldi, MG
    Redding, SW
    JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (12) : 5846 - 5848
  • [5] In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs
    Tay, S. T.
    Haryanty, T. Tanty
    Ng, K. P.
    Rohani, M. Y.
    Hamimah, H.
    MYCOSES, 2006, 49 (04) : 324 - 330
  • [6] Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela
    Calvo, BM
    Colombo, AL
    Fischman, O
    Santiago, A
    Thompson, L
    Lazera, M
    Telles, F
    Fukushima, K
    Nishimura, K
    Tanaka, R
    Myiajy, M
    Moretti-Branchini, ML
    JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (06) : 2348 - 2350
  • [7] Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole
    Chang, WN
    Huang, CR
    Lei, CB
    Lee, PY
    Chien, CC
    Chang, HW
    Chang, CS
    Lu, CH
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2004, 57 (03) : 113 - 115
  • [8] In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program
    Pfaller, MA
    Messer, SA
    Boyken, L
    Hollis, RJ
    Rice, C
    Tendolkar, S
    Diekema, DJ
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 48 (03) : 201 - 205
  • [9] In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species
    Nishi, Isao
    Sunada, Atsuko
    Toyokawa, Masahiro
    Asari, Seishi
    Iwatani, Yoshinori
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2009, 15 (01) : 1 - 5
  • [10] Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain:: 1994-1996 and 1997-2005
    Aller, A. I.
    Claro, R.
    Castro, C.
    Serrano, C.
    Colom, M. F.
    Martin-Mazuelos, E.
    CHEMOTHERAPY, 2007, 53 (04) : 300 - 305